Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

f symptoms and complications including anemia, weakness, fatigue, infection and bleeding. Bone marrow failure results in death from bleeding and infection in the majority of patients, while transformation from MDS to acute myelogenous leukemia (AML) occurs in up to 40 percent of patients. The highest incidence of MDS is in patients over 60 years of age.

According to the Aplastic Anemia and MDS International Foundation, approximately 10,000-30,000 new cases of MDS are diagnosed each year in the United States, although it is difficult to accurately determine the incidence because MDS is not a disease for which the Centers for Disease Control and Prevention (CDC) mandates reporting of cases.

About MethylGene

MethylGene Inc. (TSX:MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company focuses on some of the most promising areas of oncology such as histone deacetylase (HDAC) and kinase inhibitors. The Company's lead product is MGCD0103, an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza and Gemzar(r). MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. In addition, MethylGene has several preclinical HDAC programs in non-oncology indications such as fungal infections (clinical candidate MGCD290 in combination with azoles to overcome resistance) and Huntington's disease. The company also has a beta-lactamase program to overcome antibiotic resistance. MethylGene's development and commercialization partners include Pharmion Corporation, Taiho Pharmaceutical,

Merck and EnVivo Pharmaceuticals. Please visit our website at www.methylgene.com.

About Pharmion

Pharmion is a biophar
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:12/16/2009)... Dec. 16 A new ... manage the clinical review of specialty pharmaceuticals has ... of drugs reviewed while reducing costs. ,, AIM, ... company with health plan clients representing over 35 ... Inc. (NYSE: WLP ), adapted the ...
(Date:12/16/2009)... REYKJAVIK, Iceland, December 16 Scientists at,deCODE ... journal Nature the,discovery of a version of a ... genome (SNP) with a major impact on susceptibility ... T2D variant is not only large, but unusual:,if ... variant increases risk of,T2D by more than 30% ...
(Date:12/16/2009)... NEW YORK, December 16 ... the publication of GFT505 (80 mg/day),data ... 50 internationally,recognized expert scientists and clinicians ... the continuing role of generic lipid-modifying,treatments, ... which is commonly observed in patients ...
Breaking Medicine Technology:American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3A new bent on fusion 9637 1A new bent on fusion 9637 2Princeton team learns why some drugs pack such a punch 9635 1Princeton team learns why some drugs pack such a punch 9635 2Princeton team learns why some drugs pack such a punch 9635 3ESCO Announces Major Contract Award for Its Thermoforming Business 54966 1ESCO Announces Major Contract Award for Its Thermoforming Business 54966 2
... by the European Commission, ATRIPLA Would Represent the, First and Only Once-Daily ... ... PRINCETON, N.J., FOSTER CITY, Calif. and WHITEHOUSE STATION, N.J., Oct.,18 Bristol-Myers ... and Merck & Co., Inc. (NYSE: MRK ),announced today that the ...
... Society for Reproductive Medicine meeting could significantly improve ability to identify embryos ... patients, AFA supports efforts to bring advanced screening technology to patients as,quickly as ... ... procedures, NEW YORK, Oct. 18 According to results ...
Other Medicine Technology:European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 2European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 3European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 4European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 5European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 6European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 7European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 8European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 9European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 10American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities 2American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities 3
(Date:12/17/2009)... 17 On the heels of unveiling the ... the 2010 race, LA Marathon officials today announced a ... raising funds for causes ranging from cancer research to ... expanded charity program is in line with the vision ... has the potential to be a huge philanthropic force ...
(Date:12/17/2009)... Dec. 17 /PRNewswire-Asia/ -- China,s leading high-tech,healthcare group, ... Stock Code: 801) is pleased to announce today ... period under review, the Group,s two,associate companies made ... and NASDAQ;,its key businesses have been strengthened, with ... management operations. , Mr. ...
(Date:12/17/2009)... Brandeis University selected Jay and Maureen Neitz, the husband-and-wife ... of gene therapy to treat vision disorders, as the ... Vision Sciences. , The award is funded by a ... from Brandeis graduates Jay Pepose ,75 and Susan K. ... research fellowships in vision science. , The Neitzes, both ...
(Date:12/17/2009)... use in era of sexually explicit messaging, experts say ... and preteens spend hours sending text messages from their ... messages -- sexually explicit material, giving the messaging the ... University of Michigan researchers report. , In fact, a ... are worried about the time their children spend sending ...
(Date:12/17/2009)... firm’s Interim Leadership division as senior vice president. A seasoned executive ... assume her duties at B. E. Smith today. , ... ... Smith recently hired Deirdre Byrne to lead the firm’s Interim ... 20 years of experience in healthcare consulting, Byrne will assume her ...
Breaking Medicine News(10 mins):Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 2Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 3Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 4Health News:Golden Meditech Announces Interim Results of FY2009/10 2Health News:Golden Meditech Announces Interim Results of FY2009/10 3Health News:Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis 2Health News:'Sexting' by Kids Begets Fretting by Parents 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3
... According to the latest on breast-feeding, there is no hard and ... Most young mothers would be more than glad to ... feeding, can prove too painful for motherly feelings to override. ... a horrendous time trying to breastfeed when her daughter Deborah was ...
... United States the gays prefer to find out whether their ... than use protection to prevent catching the disease. The ... transmitting the virus, which is on the rise. ... with HIV virus and they continue to have unprotected sex. ...
... the functioning of maternity units in UK is an eye-opener ... affair in the hospitals. In a sting operation conducted by ... some alarming practices. ,Some of the maternity units ... most midwives were overburdened with work. The midwife in charge ...
... United Arab Emirates (UAE) said the government is working to ... country's prevention programme of genetic disorders. ,"We ... child's health. But the choice to have the abortion will ... to be within the religious and social environment," Ali Shakar ...
... National AIDS Control Organisation (NACO) has launched an educational ... is being implemented by all the States and Union ... is aimed at the following learning outcomes: (i) to ... process of growing up during adolescence, HIV/AIDS and drug ...
... Health Minister P.K. Sreemathi and seven others for culpable homicide ... newborns in a hospital due to infection. ... judgement on a complaint by a person regarding infant deaths ... ,The deaths were due to infection the infants contracted in ...
Other Medicine News:Health News:New Research Promises To Take The Pain Off Breast Feeding 2Health News:New Research Promises To Take The Pain Off Breast Feeding 3Health News:Unprotected Sex Among the Gays on the Rise 2Health News:United Kingdom: Maternity Units Exposed! Leaves Much to Be Desired 2Health News:Kerala Health Minister Charged for Infant Deaths in a Hospital 2
... 2000 Digoxin Assay is a ... use in the quantitative analysis ... or plasma. Kits are packaged ... Roche COBAS MIRA, COBAS MIRA ...
The Emit 2000 Digoxin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of digoxin in human serum or plasma. Kits are conveniently packaged in Olympus Reagent Cartridges ...
Liquichek Rheumatoid Factor Control is a liquid trilevel control designed to monitor rheumatoid factor testing procedures, including nephelometric and latex agglutination methods....
... The Newmarket Laboratories RPR kits use ... of lipid antigens, which will combine ... or plasma. The particles are suspended ... eliminate non - specific reactions. Positive ...
Medicine Products: